Lung Cancer

Veristrat: Current Status – pro

VeriStrat® is a blood-based predictive and prognostic proteomic test for patients with advanced non-small cell lung cancer who test negative for EGFR mutations (EGFR wild-type) or whose EGFR mutation status is unknown. Veristrat was presented in April the 3rd European Lung Cancer Conference in Geneva, Switzerland. The VeriStrat test was validated through a retrospective analysis was performed on serum samples from advanced non-squamous non-small

Read more